JP2017513831A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017513831A5 JP2017513831A5 JP2016561735A JP2016561735A JP2017513831A5 JP 2017513831 A5 JP2017513831 A5 JP 2017513831A5 JP 2016561735 A JP2016561735 A JP 2016561735A JP 2016561735 A JP2016561735 A JP 2016561735A JP 2017513831 A5 JP2017513831 A5 JP 2017513831A5
- Authority
- JP
- Japan
- Prior art keywords
- fviia
- life
- protein
- extended
- life extended
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010054265 Factor VIIa Proteins 0.000 claims 75
- 229940012414 factor viia Drugs 0.000 claims 25
- 230000002708 enhancing effect Effects 0.000 claims 16
- 210000004369 blood Anatomy 0.000 claims 14
- 239000008280 blood Substances 0.000 claims 14
- 208000032843 Hemorrhage Diseases 0.000 claims 13
- 208000034158 bleeding Diseases 0.000 claims 13
- 230000000740 bleeding effect Effects 0.000 claims 13
- 238000000034 method Methods 0.000 claims 12
- 238000003556 assay Methods 0.000 claims 6
- 230000000694 effects Effects 0.000 claims 6
- 238000001356 surgical procedure Methods 0.000 claims 6
- 229920001184 polypeptide Polymers 0.000 claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims 5
- 101800005309 Carboxy-terminal peptide Proteins 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 102000009027 Albumins Human genes 0.000 claims 3
- 108010088751 Albumins Proteins 0.000 claims 3
- 102100026735 Coagulation factor VIII Human genes 0.000 claims 2
- 208000009292 Hemophilia A Diseases 0.000 claims 2
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims 2
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims 2
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 claims 2
- 108060003951 Immunoglobulin Proteins 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 210000003743 erythrocyte Anatomy 0.000 claims 2
- 239000004023 fresh frozen plasma Substances 0.000 claims 2
- 102000018358 immunoglobulin Human genes 0.000 claims 2
- 210000002381 plasma Anatomy 0.000 claims 2
- 102100022641 Coagulation factor IX Human genes 0.000 claims 1
- 206010010356 Congenital anomaly Diseases 0.000 claims 1
- 201000003542 Factor VIII deficiency Diseases 0.000 claims 1
- 208000031220 Hemophilia Diseases 0.000 claims 1
- ZYFVLHYHXNFROE-KRWDZBQOSA-N N'-[(5S)-1-(hydroxyamino)-1-oxononan-5-yl]-N-phenylhexanediamide Chemical compound ONC(CCC[C@H](CCCC)NC(CCCCC(=O)NC1=CC=CC=C1)=O)=O ZYFVLHYHXNFROE-KRWDZBQOSA-N 0.000 claims 1
- 208000013633 acquired hemophilia Diseases 0.000 claims 1
- 125000003827 glycol group Chemical group 0.000 claims 1
- 208000009429 hemophilia B Diseases 0.000 claims 1
- 230000002439 hemostatic effect Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 229920001515 polyalkylene glycol Polymers 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 230000000717 retained effect Effects 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461978218P | 2014-04-11 | 2014-04-11 | |
| US61/978,218 | 2014-04-11 | ||
| EP14167612.2 | 2014-05-09 | ||
| EP14167612 | 2014-05-09 | ||
| EP14168389.6 | 2014-05-15 | ||
| EP14168389 | 2014-05-15 | ||
| PCT/AU2015/050137 WO2015154139A1 (en) | 2014-04-11 | 2015-03-30 | Half-life extended factor fviia protein for prevention and treatment of bleeding and dosing regimens therefor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017513831A JP2017513831A (ja) | 2017-06-01 |
| JP2017513831A5 true JP2017513831A5 (cg-RX-API-DMAC10.html) | 2018-05-17 |
Family
ID=54287020
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016561735A Pending JP2017513831A (ja) | 2014-04-11 | 2015-03-30 | 出血の予防および処置のための半減期延長型（ｈａｌｆ−ｌｉｆｅ ｅｘｔｅｎｄｅｄ）第ｆｖｉｉａ因子タンパク質、ならびに、その投与レジメン |
Country Status (12)
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2963665T3 (es) * | 2017-06-29 | 2024-04-01 | CSL Behring Lengnau AG | Régimen de dosificación de 21 días para proteínas de fusión que comprenden factor ix y albúmina humana para el tratamiento profiláctico de la hemofilia y procedimientos para ello |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9458444B2 (en) * | 2006-02-03 | 2016-10-04 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
| EP1816201A1 (en) * | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modified coagulation factor VIIa with extended half-life |
| DK2101821T3 (da) * | 2006-12-15 | 2014-10-06 | Baxter Healthcare Sa | Faktor VIIA-(poly)sialinsyre-konjugat med forlænget halveringstid in vivo |
| EP2467166A2 (en) * | 2009-08-20 | 2012-06-27 | CSL Behring GmbH | Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders |
| KR20120002129A (ko) * | 2010-06-30 | 2012-01-05 | 한미홀딩스 주식회사 | 면역글로불린 단편을 이용한 제７인자（Ｆａｃｔｏｒ Ⅶａ）약물 결합체 |
-
2015
- 2015-03-30 JP JP2016561735A patent/JP2017513831A/ja active Pending
- 2015-03-30 CA CA2944174A patent/CA2944174A1/en not_active Abandoned
- 2015-03-30 WO PCT/AU2015/050137 patent/WO2015154139A1/en not_active Ceased
- 2015-03-30 CN CN201580018873.8A patent/CN106164097A/zh not_active Withdrawn
- 2015-03-30 EP EP15775929.1A patent/EP3129408A4/en not_active Withdrawn
- 2015-03-30 MX MX2016013281A patent/MX2016013281A/es unknown
- 2015-03-30 AU AU2015245941A patent/AU2015245941A1/en not_active Abandoned
- 2015-03-30 SG SG11201608006QA patent/SG11201608006QA/en unknown
- 2015-03-30 RU RU2016144159A patent/RU2016144159A/ru not_active Application Discontinuation
- 2015-03-30 KR KR1020167031632A patent/KR20160143820A/ko not_active Withdrawn
- 2015-03-30 BR BR112016023158A patent/BR112016023158A2/pt not_active Application Discontinuation
- 2015-03-30 US US15/302,597 patent/US20170042981A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tol et al. | A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity | |
| JP2020002171A5 (cg-RX-API-DMAC10.html) | ||
| CN104010656B (zh) | 使用免疫球蛋白和c1-抑制剂的联合疗法 | |
| JP2014515763A5 (cg-RX-API-DMAC10.html) | ||
| Leissinger et al. | Rituximab for treatment of inhibitors in haemophilia A | |
| TW202241504A (zh) | 用於因第viii凝血因子及/或活化的第viii凝血因子的活性降低或欠缺而發病及/或進展的疾病之預防及/或治療之醫藥組成物 | |
| Herzog et al. | First treatment of relapsing rapidly progressive IgA nephropathy with eculizumab after living kidney donation: a case report | |
| Yotsu et al. | Case series of patients with chronic foot ulcers treated with autologous platelet‐rich plasma | |
| JP2016514132A5 (cg-RX-API-DMAC10.html) | ||
| JP2005535588A5 (cg-RX-API-DMAC10.html) | ||
| CN105873583A (zh) | 用于降低慢性肾病患者的心力衰竭的枸橼酸铁 | |
| Son et al. | SAMiRNA targeting amphiregulin alleviate total-body-irradiation-induced renal fibrosis | |
| JP2011506436A (ja) | 細胞傷害性ｔリンパ球抗原４（ｃｔｌａ４）に対する抗体と組み合わせられたアルファチモシンペプチドによる黒色腫の処置の方法 | |
| AU2016259320A1 (en) | Pharmaceutical compositions | |
| AU2014267349A1 (en) | Agent and method for treating herpes | |
| Puri et al. | Recurrent aphthous stomatitis: Therapeutic management from topicals to systemics | |
| PANCORBO et al. | Digoxin pharmacokinetics in continuous peritoneal dialysis | |
| Sanjay et al. | Lockdown effects on a patient receiving immunosuppression for unilateral HLA-B27 associated uveitis during COVID-19 pandemic | |
| RU2016144159A (ru) | Белок-фактор fviia с увеличенным периодом полужизни для профилактики и лечения кровотечения, и его режимы дозирования | |
| Brezis et al. | Nightmares from digoxin | |
| Holford | Quinidine-digoxin interaction | |
| Baran et al. | Predictors of early renal insufficiency in cardiac transplant recipients initiated on tacrolimus | |
| Shima et al. | Clinical experiences of bixalomer usage at our hospital | |
| CA2848510C (en) | Combination therapy using immunoglobulin and c1-inhibitor | |
| ROSANSKY et al. | Sickle cell trait with episodic acute renal failure and type IV renal tubular acidosis |